|
|
|
|
| LEADER |
06123nam a22005415i 4500 |
| 001 |
978-3-030-63046-1 |
| 003 |
DE-He213 |
| 005 |
20210622210358.0 |
| 007 |
cr nn 008mamaa |
| 008 |
210331s2021 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783030630461
|9 978-3-030-63046-1
|
| 024 |
7 |
|
|a 10.1007/978-3-030-63046-1
|2 doi
|
| 050 |
|
4 |
|a QR180-189.5
|
| 072 |
|
7 |
|a MJCM
|2 bicssc
|
| 072 |
|
7 |
|a MED044000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCM
|2 thema
|
| 082 |
0 |
4 |
|a 616.079
|2 23
|
| 245 |
1 |
0 |
|a Lung Inflammation in Health and Disease, Volume I
|h [electronic resource] /
|c edited by Yong-Xiao Wang.
|
| 250 |
|
|
|a 1st ed. 2021.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2021.
|
| 300 |
|
|
|a XV, 409 p. 54 illus., 38 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Advances in Experimental Medicine and Biology,
|x 0065-2598 ;
|v 1303
|
| 505 |
0 |
|
|a 1. Potential role of mast cells in regulating corticosteroid insensitivity in severe asthma -- 2. Galectin-3 Promotes ROS, Inflammation and Vascular Fibrosis in Pulmonary Arterial Hypertension -- 3. Anti-Inflammatory Effects of Statins in Lung Vascular Pathology: From Basic Science to Clinical Trials -- 4. Evolving Schema for Employing Network Biology Approaches to Understand Pulmonary Hypertension -- 5. Pulmonary Inflammation and KRAS Mutation in Lung Cancer -- 6. microRNA Targets for Asthma Therapy -- 7. Roles of genetic predisposition in the sex-bias of pulmonary pathophysiology, as a function of estrogens -- 8. Hypercapnic respiratory failure-driven skeletal muscle dysfunction: It is time for animal mod-els-based mechanistic research -- 9. Role of airway smooth muscle in inflammation related to asthma and COPD -- 10. Systemic Sclerosis and Pulmonary Disease -- 11. Innate Lymphoid Cells in airway inflammation -- 12. Sjogren’s Syndrome and pulmonary disease -- 13. Redox Regulation, Oxidative Stress and Inflammation in Group 3 Pulmonary Hypertension -- 14. Sex-Steroid Signaling in Lung Diseases and Inflammation -- 15. Cytokines, Chemokines and Inflammation in Pulmonary Arterial Hypertension -- 16. Interactive roles of CaMKII/Ryanodine Receptor Signaling and Inflammation in Lung Diseases -- 17. Reciprocal Correlations of Inflammatory and Calcium Signaling in Asthma Pathogenesis -- 18. Crosstalk between Lung and Extrapulmonary Organs in Infection and Inflammation -- 19. Inflammation in Pulmonary Arterial Hypertension -- 20. Lysophospholids in Lung Inflammatory Diseases.
|
| 520 |
|
|
|a Respiratory diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma, the most common chronic disease. Each year, tens of millions of people develop and can die from respiratory infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for those affected. Current treatment options for lung diseases are neither always effective, nor often condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases are not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung diseases, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, fellows, and students with new perspectives and concepts. The editor hopes this book will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Human physiology.
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
|
0 |
|a Respiratory organs—Diseases.
|
| 650 |
1 |
4 |
|a Immunology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B14000
|
| 650 |
2 |
4 |
|a Human Physiology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B13004
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B1700X
|
| 650 |
2 |
4 |
|a Pneumology/Respiratory System.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/H33134
|
| 700 |
1 |
|
|a Wang, Yong-Xiao.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer Nature eBook
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030630454
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030630478
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030630485
|
| 830 |
|
0 |
|a Advances in Experimental Medicine and Biology,
|x 0065-2598 ;
|v 1303
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-63046-1
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 912 |
|
|
|a ZDB-2-SXB
|
| 950 |
|
|
|a Biomedical and Life Sciences (SpringerNature-11642)
|
| 950 |
|
|
|a Biomedical and Life Sciences (R0) (SpringerNature-43708)
|
